de Invesco Ligand Pharmaceuticals LGND Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 380 M | Comprar |
1,201,644
+378,040
| +46% | +USD 89.1 M | 0.03% | 468 |
|
|
2026
Q1 | USD 164 M | Comprar |
823,604
+307,140
| +59% | +USD 60.8 M | 0.02% | 722 |
|
|
2025
Q4 | USD 97.6 M | Comprar |
516,464
+138,169
| +37% | +USD 26.5 M | 0.01% | 840 |
|
|
2025
Q3 | USD 67 M | Comprar |
378,295
+148,437
| +65% | +USD 22.1 M | 0.01% | 975 |
|
|
2025
Q2 | USD 26.1 M | Comprar |
229,858
+27,030
| +13% | +USD 2.89 M | ﹤0.01% | 1311 |
|
|
2025
Q1 | USD 21.3 M | Comprar |
202,828
+8,473
| +4% | +USD 958 k | ﹤0.01% | 1408 |
|
|
2024
Q4 | USD 20.8 M | Comprar |
194,355
+5,627
| +3% | +USD 636 k | ﹤0.01% | 1465 |
|
|
2024
Q3 | USD 18.9 M | Comprar |
188,728
+15,917
| +9% | +USD 1.6 M | ﹤0.01% | 1487 |
|
|
2024
Q2 | USD 14.6 M | Vender |
172,811
-42,284
| -20% | -USD 3.36 M | ﹤0.01% | 1590 |
|
|
2024
Q1 | USD 15.7 M | Comprar |
215,095
+194
| +0.1% | +USD 14.3 k | ﹤0.01% | 1567 |
|
|
2023
Q4 | USD 15.3 M | Vender |
214,901
-3,886
| -2% | -USD 229 k | ﹤0.01% | 1558 |
|
|
2023
Q3 | USD 13.1 M | Vender |
218,787
-3,196
| -1% | -USD 210 k | ﹤0.01% | 1585 |
|
|
2023
Q2 | USD 16 M | Vender |
221,983
-4,120
| -2% | -USD 309 k | ﹤0.01% | 1492 |
|
|
2023
Q1 | USD 16.6 M | Vender |
226,103
-783
| -0.3% | -USD 55.7 k | ﹤0.01% | 1446 |
|
|
2022
Q4 | USD 15.2 M | Vender |
226,886
-79,401
| -26% | -USD 5.16 M | ﹤0.01% | 1540 |
|
|
2022
Q3 | USD 16.5 M | Vender |
306,287
-44,825
| -13% | -USD 2.64 M | 0.01% | 1456 |
|
|
2022
Q2 | USD 19.5 M | Comprar |
351,112
+39,223
| +13% | +USD 2.23 M | 0.01% | 1389 |
|
|
2022
Q1 | USD 21.9 M | Vender |
311,889
-23,157
| -7% | -USD 1.68 M | 0.01% | 1456 |
|
|
2021
Q4 | USD 32.3 M | Vender |
335,046
-99,962
| -23% | -USD 9.23 M | 0.01% | 1246 |
|
|
2021
Q3 | USD 37.8 M | Comprar |
435,008
+53,996
| +14% | +USD 4.18 M | 0.01% | 1172 |
|
|
2021
Q2 | USD 31.2 M | Comprar |
381,012
+59,181
| +18% | +USD 4.92 M | 0.01% | 1333 |
|
|
2021
Q1 | USD 30.6 M | Comprar |
321,831
+11,144
| +4% | +USD 1.05 M | 0.01% | 1299 |
|
|
2020
Q4 | USD 19.3 M | Comprar |
310,687
+14,802
| +5% | +USD 844 k | 0.01% | 1450 |
|
|
2020
Q3 | USD 17.6 M | Comprar |
295,885
+45,751
| +18% | +USD 3.12 M | 0.01% | 1370 |
|
|
2020
Q2 | USD 17.5 M | Comprar |
250,134
+9,210
| +4% | +USD 584 k | 0.01% | 1339 |
|
|
2020
Q1 | USD 10.9 M | Vender |
240,924
-78,002
| -24% | -USD 4.42 M | ﹤0.01% | 1490 |
|
|
2019
Q4 | USD 20.7 M | Comprar |
318,926
+270,943
| +565% | +USD 18.1 M | 0.01% | 1411 |
|
|
2019
Q3 | USD 2.98 M | Vender |
47,983
-540,339
| -92% | -USD 33.9 M | ﹤0.01% | 2415 |
|
|
2019
Q2 | USD 41.9 M | Comprar |
588,322
+521,413
| +779% | +USD 38.4 M | 0.01% | 1095 |
|
|
2019
Q1 | USD 5.25 M | Vender |
66,909
-136,948
| -67% | -USD 10.4 M | ﹤0.01% | 1976 |
|
|
2018
Q4 | USD 17.3 M | Vender |
203,857
-505,560
| -71% | -USD 53.9 M | 0.01% | 1213 |
|
|
2018
Q3 | USD 121 M | Comprar |
709,417
+235,912
| +50% | +USD 35.6 M | 0.04% | 503 |
|
|
2018
Q2 | USD 61.2 M | Comprar |
473,505
+119,335
| +34% | +USD 13.3 M | 0.02% | 755 |
|
|
2018
Q1 | USD 36.5 M | Comprar |
354,170
+16,711
| +5% | +USD 1.65 M | 0.01% | 883 |
|
|
2017
Q4 | USD 28.8 M | Comprar |
337,459
+17,590
| +5% | +USD 1.52 M | 0.01% | 1011 |
|
|
2017
Q3 | USD 27.2 M | Vender |
319,869
-28,812
| -8% | -USD 2.28 M | 0.01% | 1045 |
|
|
2017
Q2 | USD 26.4 M | Vender |
348,681
-222,925
| -39% | -USD 15.6 M | 0.01% | 1066 |
|
|
2017
Q1 | USD 37.7 M | Vender |
571,606
-89,135
| -13% | -USD 5.86 M | 0.01% | 917 |
|
|
2016
Q4 | USD 41.9 M | Vender |
660,741
-135,145
| -17% | -USD 8.53 M | 0.01% | 870 |
|
|
2016
Q3 | USD 50.7 M | Comprar |
795,886
+39,089
| +5% | +USD 2.87 M | 0.02% | 750 |
|
|
2016
Q2 | USD 56.3 M | Vender |
756,797
-159,332
| -17% | -USD 11.8 M | 0.02% | 705 |
|
|
2016
Q1 | USD 61.2 M | Vender |
916,129
-270,213
| -23% | -USD 16.4 M | 0.02% | 647 |
|
|
2015
Q4 | USD 80.2 M | Vender |
1,186,342
-271,083
| -19% | -USD 16.7 M | 0.03% | 590 |
|
|
2015
Q3 | USD 77.9 M | Vender |
1,457,425
-60,648
| -4% | -USD 3.68 M | 0.03% | 573 |
|
|
2015
Q2 | USD 95.6 M | Vender |
1,518,073
-330,271
| -18% | -USD 18 M | 0.04% | 531 |
|
|
2015
Q1 | USD 88.9 M | Comprar |
1,848,344
+390,541
| +27% | +USD 15 M | 0.03% | 554 |
|
|
2014
Q4 | USD 48.4 M | Comprar |
1,457,803
+175,331
| +14% | +USD 5.7 M | 0.02% | 812 |
|
|
2014
Q3 | USD 37.6 M | Comprar |
1,282,472
+408,651
| +47% | +USD 13.6 M | 0.02% | 928 |
|
|
2014
Q2 | USD 34 M | Vender |
873,821
-154,980
| -15% | -USD 6.29 M | 0.01% | 994 |
|
|
2014
Q1 | USD 43.2 M | Comprar |
1,028,801
+172,857
| +20% | +USD 7.21 M | 0.02% | 854 |
|
|
2013
Q4 | USD 28.1 M | Comprar |
855,944
+77,360
| +10% | +USD 2.52 M | 0.01% | 1073 |
|
|
2013
Q3 | USD 21 M | Vender |
778,584
-156,813
| -17% | -USD 4.41 M | 0.01% | 1140 |
|
|
2013
Q2 | USD 21.8 M | Comprar |
+935,397
| Nuevas | +USD 16.8 M | 0.01% | 1069 |
|
Otros fondos que tienen LGND en su cartera
Posición de Invesco en LGND: resumen de T2 2026
Invesco aumentó su participación en Ligand Pharmaceuticals (LGND) en 46% durante T2 2026, al comprar aproximadamente USD 89.1 M y elevar la posición a 1,201,644 acciones con un valor de USD 380 M. La posición representa 0.03% de la cartera y ocupa el puesto #468.
Invesco reportó por primera vez una posición en LGND en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 418 fondos que sigue Wall St. Rank mantienen una posición en LGND.
- Al cierre de T2 2026, Invesco tenía 1,201,644 acciones de Ligand Pharmaceuticals con un valor de USD 380 M.
- Invesco compró 378,040 acciones de Ligand Pharmaceuticals en T2 2026, por un monto estimado de USD 89.1 M.
- Ligand Pharmaceuticals representó 0.03% de la cartera de Invesco en T2 2026 y fue su posición número 468.
- Invesco reportó por primera vez una posición en Ligand Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 418 fondos que sigue Wall St. Rank tenían Ligand Pharmaceuticals en cartera.
Según el Informe 13F de Invesco correspondiente a T2 2026, presentado el 14 ago 2026.